Pfizer Inc. will acquire Medivation, a biopharmaceutical company whose portfolio includes enzalutamide (Xtandi), talazoparib, and pidilizumab.1

Enzalutamide, an androgen receptor inhibitor, is approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic castration-resistant prostate cancer. It is also being evaluated in phase 2 trials for the potential treatment of advanced breast cancer and hepatocellular carcinoma.

“The proposed acquisition of Medivation will build upon Pfizer’s success with our Ibrance (palbociclib) launch in HR+/HER2- metastatic breast cancer and with our strong immuno-oncology portfolio, and will transform Pfizer into a leading oncology company,” said Albert Bourla, group president of Pfizer Innovative Health.

Talazoparib, a highly potent PARP inhibitor, is under phase 3 investigation for the treatment of BRCA-mutated breast cancer, and pidilizumab is being developed for the treatment of diffuse large B-cell lymphoma and other hematologic malignancies, including follicular lymphoma and multiple myeloma.

RELATED: USPSTF Recommendations Linked With Decrease in Prostate Cancer Incidence Rates

“We believe that Pfizer is the ideal partner to extend the reach of our blockbuster Xtandi franchise and take our promising, late-stage assets – talazoparib and pidiluzimab – to their next stages of development so that they can be made available to patients as quickly as possible,” said David Hung, MD, founder, president, and CEO of Medivation.                      

Reference

  1. Pfizer to acquire Medivation. Pfizer website. http://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_medivation. Updated August 22, 2016. Accessed August 23, 2016.